| Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma (NCT05112601) | National Cancer Institute (NCI) | 2022-06-02 |
| A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα) (NCT05001282) | Elucida Oncology | 2021-09-13 |
| Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer (NCT03914612) | National Cancer Institute (NCI) | 2019-08-22 |
| Determine the Utility of Liquid Biopsies and Tumor Molecular Profiling in Predicting Recurrence in Endometrial Cancers (NCT05049538) | M.D. Anderson Cancer Center | 2019-06-18 |
| Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer (NCT03422198) | University of Utah | 2018-02-02 |
| Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer (NCT02874430) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2016-06-08 |
| Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol (NCT02501954) | Women's Cancer Care Associates, LLC | 2015-03-01 |
| TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors (NCT02142803) | National Cancer Institute (NCI) | 2014-05-20 |
| Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer (NCT02065687) | Gynecologic Oncology Group | 2014-03-17 |
| Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers (NCT02020707) | Mayo Clinic | 2014-02-24 |
| Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer (NCT02059265) | National Cancer Institute (NCI) | 2014-02-14 |
| Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer (NCT01935973) | National Cancer Institute (NCI) | 2013-09-30 |
| Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer (NCT01935934) | National Cancer Institute (NCI) | 2013-05-08 |
| PET/CT and Lymph Node Mapping in Finding Lymph Node Metastasis in Patients With High-Risk Endometrial Cancer (NCT01737619) | M.D. Anderson Cancer Center | 2013-04-03 |
| Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer (NCT01642082) | Gynecologic Oncology Group | 2012-09-01 |
| Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer (NCT01225887) | Gynecologic Oncology Group | 2011-10-01 |
| Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer (NCT01440998) | National Cancer Institute (NCI) | 2011-09-20 |
| Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer (NCT01307631) | National Cancer Institute (NCI) | 2011-03-01 |
| Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer (NCT01132820) | National Cancer Institute (NCI) | 2010-06-01 |
| Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer (NCT01005329) | National Cancer Institute (NCI) | 2009-11-06 |
| Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer (NCT00977574) | National Cancer Institute (NCI) | 2009-09-14 |
| Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer (NCT01011933) | National Cancer Institute (NCI) | 2009-09-01 |
| Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer (NCT00942357) | Gynecologic Oncology Group | 2009-06-29 |
| Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer (NCT00807768) | Gynecologic Oncology Group | 2009-03-23 |
| Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial Cancer (NCT00820898) | Gynecologic Oncology Group | 2009-02-01 |
| Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer (NCT00575952) | Gynecologic Oncology Group | 2008-01-17 |
| Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer (NCT00005840) | Gynecologic Oncology Group | 2000-07-01 |
| Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer (NCT00005830) | Gynecologic Oncology Group | 2000-07-01 |
| Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer (NCT00006011) | Gynecologic Oncology Group | 2000-07-01 |